$0.88 -0.01 (-1.00%) Ampio Pharmaceuticals Inc - NYSE Amex Equities

Sep. 23, 2016 | 04:00 PM
Last Trade: 0.88
Trade Time: Sep 23 04:00 PM Eastern Daylight Time
Change: -0.01 (-1.00%)
Prev Close: 0.89
Open: 0.90
Bid: 0.87
Ask: 1.06
  1. No results found.
  1. Ampio Pharmaceuticals, Inc. Announces Updates On the Regulatory Path for FDA Approval of Optina™, an Oral Treatment for Diabetic Macular Edema (DME)

    Benzinga | Oct. 14, 2015 | 09:02AM EST
  2. Morning Market Gainers

    Benzinga | Sep. 22, 2015 | 09:57AM EST
  3. AMPIO Receives Special Protocol Assessment from FDA; Commences Second Phase III pivotal trial of Ampion

    Benzinga | Sep. 22, 2015 | 08:04AM EST
  4. Morning Market Gainers

    Benzinga | May. 21, 2015 | 09:49AM EST
  5. Morning Market Losers

    Benzinga | Apr. 20, 2015 | 09:51AM EST
  6. Ampio Offers Update on Phase III Multicenter, Double-Blind STEP Study of Ampion

    Benzinga | Sep. 2, 2014 | 07:57AM EST
  7. Ampio Pharma Announces Responses to Questions Related to STEP Study

    Benzinga | Aug. 25, 2014 | 08:03AM EST
  8. Morning Market Losers

    Benzinga | Aug. 22, 2014 | 09:58AM EST
  9. Benzinga's Top Downgrades

    Benzinga | Aug. 22, 2014 | 09:44AM EST
  10. Jefferies Downgrades Ampio Pharmaceuticals To Hold

    Benzinga | Aug. 22, 2014 | 08:33AM EST
  11. Morning Market Losers

    Benzinga | Aug. 21, 2014 | 10:02AM EST
  12. Ampio Pharmaceuticals' Vyrix Enters into an Agreement with Paladin Labs for Exclusive Rights to Zertane in Canada

    Benzinga | Apr. 10, 2014 | 08:05AM EST
  13. Ampio Pharma to Present Results of 20 Weeks Extension of Ampion SPRING Study at Western Orthopedic Association

    Benzinga | Apr. 9, 2014 | 08:11AM EST
  14. Ampio Pharmaceuticals Spins-Off Sexual Dysfunction Business

    Benzinga | Dec. 13, 2013 | 13:01PM EST
  15. Ampio Pharma Announces Results from Panel Review of the Interim Analysis of the Optina(TM) Trial, FDA Agrees to 505(B) 2 Pathway

    Benzinga | Oct. 7, 2013 | 08:06AM EST
Trading Center